Sihai network

What is the punishment for the long-lived creatures? What's the matter with the rabies vaccine for f

Original title: Shenzhen Stock Exchange denounces Changsheng biology: major defects in internal control

Beijing, July 20 (Xinhua) - according to the official micro blog of Shenzhen Stock Exchange, Shenzhen Stock Exchange has launched a disciplinary procedure to publicly condemn Changsheng biological company and related parties.

On July 15, the State Drug Administration announced the illegal production of "freeze dried human rabies vaccine" by Changchun Changsheng Biotechnology Co., Ltd. (hereinafter referred to as Changchun Changsheng), a subsidiary of Changsheng Biotechnology Co., Ltd. (hereinafter referred to as the company). According to the report, the State Drug Administration organized the inspection of Changchun Changsheng, and found that the production of "freeze-dried human rabies vaccine" in Changchun Changsheng was in violation of the "drug production quality management specifications" such as falsification of records. Changchun Changsheng involved vaccine sales accounted for nearly a quarter of the domestic market, and the report issued a high degree of concern from the media and consumers.

At present, Jilin food and drug administration has withdrawn Changchun Changsheng's GMP certificate and ordered to stop the production of rabies vaccine. In addition, Changchun Changsheng's "adsorptive combined vaccine against DPT" does not meet the requirements after inspection and potency determination. Jilin food and drug administration has imposed administrative penalties such as confiscating illegal income from product inventory and fines on the company.

SZSE shall take regulatory measures as soon as possible: first, inquire the company's situation by telephone, and require immediate disclosure and response of the notified matters; second, send a letter of concern to the company twice in a row to urge the company to verify the specific situation of the products involved, whether the disclosure of major matters is timely and the impact of administrative penalty on the company; Third, the company is required to disclose the progress in time and fulfill the obligation of information disclosure according to the on-site supervision of the drug regulatory department.

In the early stage, during the review of the company's 2017 annual report, szpex has paid attention to the significant growth of the company's vaccine sales and the fact that the R & D expenditure is different from the peer's large purchase of financial products, etc., and has sent the annual report inquiry letter to the company to require the company to supplement the explanation and disclose to the public. After a comprehensive review and verification of the company's information disclosure, it was found that the company failed to disclose the information investigated by the relevant authorities in time and there were major defects in internal control. The Shenzhen Stock Exchange has launched a disciplinary procedure to denounce the company and related parties publicly because the company is suspected of violating the relevant provisions such as the stock listing rules, the guidelines for the standardized operation of listed companies on the SME board and so on.